2029 年全球Peptide治疗市场、药物剂量、价格和临床试验见解

到 2029 年，全球Peptide治疗市场预计将达到 600 亿美元。

在充满活力的製药产业中，Peptide类药物作为创新和治疗潜力的指标脱颖而出。 这些特殊的治疗剂因其广泛的应用和独特的优势而引起了人们的广泛关注。 □药物提供了一种精确且个人化的治疗方法，从治疗代谢紊乱到治疗癌症等复杂疾病。 因此，对于製药业来说，了解Peptide在市场上日益增长的重要性以充分发挥其潜力变得非常重要，并且了解它所具有的革命性影响也变得非常重要。

曾经隐藏在小分子和大蛋白疗法的阴影下的Peptide最近已成为製药领域的新增长前沿。 Peptide已展现出治疗、诊断和治疗功效，开启了精准医学的新时代。 这些适应性分子透过提供有针对性的治疗介入措施，在治疗多种疾病状态中发挥重要作用。 除了其治疗潜力之外，Peptide还照亮了诊断领域，充当检测特定生物标记和疾病的灯塔。 治疗和诊断能力的融合催生了治疗诊断学的进化概念，其中□既充当治疗师又充当嚮导，为个性化和有效的医疗保健解决方案指明了道路。

研究和技术的进步推动了Peptide药物开发的不断发展。 组合化学和高通量筛选有助于发现具有药物潜力的新Peptide序列。 此外，Peptide合成製程的进步提高了生产效率，并解决了过去有关可扩展性和成本效益的问题。 计算工具和结构生物学在Peptide设计中的整合加速了先导化合物的鑑定并缩短了药物开发所需的时间。

将人工智慧融入多□药物研发，开启了效率与创新的新时代。 机器学习演算法分析大量资料集并预测具有高结合亲和力的Peptide结构，从而提高候选药物的成功率。 此外，人工智慧还可以帮助识别潜在的不良事件并优化药物动力学特性，有助于Peptide治疗药物整体品质的提升。 ProteinQure 等製药公司正在使用计算工具来开发广泛的Peptide疗法组合，而 Space Peptides 等其他製药公司正在使用机器来设计和製造高品质的Peptide药物。我们提供允许使用学习和人工智慧工具的合约服务。

全球Peptide治疗产品线的快速扩张证明了主要製药公司对Peptide药物的兴趣日益浓厚。 此外，近几个月来，製药业的研究合作和策略联盟激增，其中一些涉及礼来（Eli Lilly）和阿斯特捷利康（AstraZeneca）等着名製药公司。 认识到Peptide在解决未满足的医疗需求方面的潜力，领先公司正在积极寻求透过合资、许可协议和收购来扩大其Peptide产品组合，从而使他们能够汇集资源并整合知识，以加速Peptide的开发和商业化药物。

多□药物有望在全球医药市场的未来前景中发挥重要作用。 随着分子层面阐明疾病原因不断取得进展的同时，Peptide的精准靶向能力将得到体现，并将成为个人化医疗的基石。 □工程的持续进步，加上人工智慧的引入，几乎肯定会导致高效且耐受性良好的治疗方法的开发。 随着製药业转向以患者为中心的范式，Peptide药物的适应性和特异性使它们成为不断变化的医疗保健领域的领导者。 Peptide的治疗适应性和高安全性使其成为寻求满足患者多样化医疗需求的製药公司的有吸引力的选择。

总之，Peptide医学领域的旅程揭示了广泛的创新和可能性。 当我们进入医学新时代时，Peptide不仅仅是治疗剂或诊断剂，而且正在成为医疗保健范式转变的先兆。 未来，Peptide将在个人化医疗、标靶治疗和不断扩大的精准医疗领域中发挥关键作用。 人工智慧等尖端技术与Peptide固有的多样性相结合，为无与伦比的发展打开了大门。 □医学的不断发展的故事描绘了一个令人着迷的未来愿景，其中这些分子继续突破医学可能性的界限，提供创新的治疗方法和乐观的前景。

本报告分析了全球Peptide治疗市场，预测了全球和区域市场规模趋势（年度/季度），并提供了各种Peptide临床试验进展资讯（按国家和适应症）。我们正在调查以下资讯主要Peptide产品的资讯（专利、可用性、成本、剂量、销售等）、主要开发平台和主要公司简介。

目录

第一章多Peptide药物概述

• 历史、发展、演变
• 核准的多Peptide药物

第 2 章Peptide药物：治疗、诊断、治疗诊断的潜力、对市场的影响

• 治疗潜力与市场影响
• 诊断潜力与市场影响
• 治疗潜力与市场影响

第三章□类药物的全球临床试验与市场趋势：依适应症分类

• 遗传性疾病
• 癌症
• 微生物感染
• 自体免疫疾病
• 代谢紊乱
• 神经退化性疾病

第 4 章基于Peptide的治疗方法

• Peptide类激素
• Peptide药物结合物
• Peptide疫苗
• Peptide激动剂
• Peptide适配体
• 多□抗体

第五章全球Peptide治疗市场展望

• 当前市场趋势与驱动因素
• 未来的发展道路

第六章多Peptide治疗药物市场状况：依地区

• 美国
• 欧盟
• 中国
• 日本
• 韩国
• 英国
• 印度
• 中东
• 加拿大
• 澳大利亚

第七章全球Peptide疗法临床试验概述

• 依国家/地区
• 适应症
• 阶段
• 优先状态
• 治疗课程

第 8 章：已上市Peptide药物的讨论：专利、可用性、成本、剂量和销售的见解

• Bylvay
  • 摘要
  • 价格趋势与用量分析
  • 销售分析
• Parsabiv
• Bydureon BCise
• Linzess
• Increlex
• Terlivaz
• Empaveli
• Voxzogo
• Imcivree
• Trulicity
• Ozempic
• Wegovy
• Tresiba
• Rybelsus
• Xultophy
• Victoza
• Ryzodeg
• Fiasp
• Lantus
• Toujeo

第九章□治疗药物开发技术与平台

• Biodrug Design Accelerator - Fujitsu/PeptiDream
• T-Win (R) Technology - IO Biotech
• Numatech - Numaferm
• ProteinStudio - ProteinQure
• The Magnifier NφΦ (TM) - Nuritas
• PepPower - GenScript
• Unnamed Peptide Platform - Zealand Pharma
• PDPS (Peptide Discovery Platform System) - PeptiDream
• Veneno Suite - Veneno Technologies
• SmartDepot (TM) Technology - Peptron
• Bicycles - Bicycle Therapeutics
• RALA Technolgy - pHion Therapeutics
• Discovery Platform - Orbit Discovery
• Imotopes - Imcyse
• Nautilus - Peptilogics
• Swarm Intelligence 2.0 - Pepticom
• streaMLine Platform - Gubra
• Precision Endocrine Peptides (PEPs) - MBX Biosciences
• pHLIP (pH-Low Insertion Peptides) - pHLIP
• alphalex - Cybrexa

第10章环□临床试验分析：依国家、适应症及分期划分

• 调查
• 临床前
• 第一阶段
• 第一/二期
• 第二阶段
• 第二/第三阶段
• 第三阶段
• 註册前
• 已註册
• 已上市

第11章Peptide激素临床试验分析：依国家、适应症及分期划分

第十二章Peptide临床试验分析：依国家、适应症及分期

第十三章胰高血糖素样Peptide临床试验分析：依国家、适应症及分期划分

第 14 章寡□临床试验分析：依国家、适应症和分期

第十五章脂□临床试验分析：依国家、适应症及分期

第 16 章二□临床试验分析：依国家、适应症和分期划分

第十七章缩□临床试验分析：依国家、适应症和分期划分

第十八章糖□临床试验分析：依国家、适应症及分期

第十九章Peptide疫苗临床试验分析：依国家、适应症及分期划分

第 20 章Peptide片段临床试验分析：依国家、适应症和分期划分

第 21 章阿片□临床试验分析：依国家、适应症和分期划分

第22章利钠□临床试验分析：依国家、适应症及分期划分

第 23 章神经Peptide临床试验分析：依国家、适应症和分期

第24章抗菌阳离子Peptide临床试验分析：依国家、适应症及分期划分

第 25 章Peptide水解□临床试验分析：依国家、适应症和分期划分

第26章Peptide适体

第27章细胞间讯号Peptide临床试验分析：依国家、适应症及分期划分

第28章Peptide类抗生素临床试验分析：依国家、适应症及分期划分

第29章Peptide药物偶联物临床试验分析：依国家、适应症及分期划分

第30章双环□临床试验分析：依国家、适应症及分期划分

第31章多种Peptide临床试验分析：依国家、适应症及分期划分

第32章竞争格局

• AbbVie
• Adocia
• Amgen
• Antlia Bioscience
• AsclepiX Therapeutics
• AstraZeneca
• Bicycle Therapeutics
• Biohaven Labs
• Bristol-Myers Squibb
• Carmot Therapeutics
• Eli Lilly and Company
• Ferring Pharmaceuticals
• Gan&Lee Pharmaceuticals
• GEROPHARM
• Hanmi Pharmaceutical
• HEC Pharm
• Heidelberg Pharma AG
• ImCyse
• Janux Therapeutics
• Kine Sciences
• Lactocore
• Maxwell Biosciences
• Merck & Co
• Novartis
• Novo Nordisk
• Oryn Therapeutics
• Palatin Technologies
• PeptiDream
• Pfizer
• Priavoid
• Primary Peptides
• Protagonist Therapeutics
• Roche
• Sanofi
• Sapience Therapeutics
• Seagen
• Shaanxi Micot Technology Co
• Stuart Therapeutics
• Takeda
• Zealand Pharma

“Global Peptide Therapeutics Market, Drug Dosage, Price & Clinical Trials Insight 2029” Reports Findings & Highlights:

• Global Peptide Therapeutics Market Opportunity: > USD 80 Billion By 2029

• Global & Regional Peptide Therapeutics Market Outlook

• Insight On Peptides In Clinical Trials By Country, Indication & Phase: > 900 Peptides In Trials

• Comprehensive Insight On Peptides Drugs Available in Market: > 200 Peptides

• Marketed Peptide Drugs Insight: Patent, Availability, Cost, Dosage, & Sales Insight

• Global, Regional, Annual & Quarterly Sales Insights

• Peptide Therapeutics Development Technologies Platform

• Global Peptide Drugs Clinical Research & Market Trends by Indication

In the dynamic pharmaceutical landscape, peptide drugs stand out as an indicator of innovation and therapeutic potential. These exception therapeutic agents have received a lot of interest due to their wide range of applications and distinct advantages. Peptide drugs provide a precise and personalized approach to therapy, from treating metabolic abnormalities to tackling complex diseases like cancer. As a result, it has become important for the pharmaceutical industry to understand the growing significance of peptides in the market to exploit their full potential, and also the revolutionary influence they are poised to have in the constantly evolving environment of healthcare.

Once overshadowed by small molecule and large protein based therapeutics, peptides have emerged as the new growth frontier of the pharmaceutical realm in the recent years. They have demonstrated therapeutic, diagnostic and theranostic properties, ushering in a new era of precision medicine. These adaptable molecules serve a critical role in treating a wide range of medical conditions by providing targeted therapeutic interventions. Beyond their treatment prowess, peptides illuminate the diagnostic landscape, serving as beacons in the detection of specific biomarkers and diseases. The convergence of therapeutic and diagnostic capabilities gives rise to the evolutionary concept of theranostics, where peptides act as both healers and guides, navigating the path toward personalized and effective healthcare solutions.

The continuous evolution of peptide drug development is fuelled by advancements in research and technology. Combinatorial chemistry and high-throughput screening have aided in the discovery of new peptide sequences with medicinal promise. Furthermore, advances in peptide synthesis processes have increased manufacturing efficiency, addressing historical issues with scalability and cost-effectiveness. The integration of computational tools and structure biology in peptide design has sped up the identification of lead compounds, reducing the time required for drug development.

The incorporation of artificial intelligence in peptide drug development has ushered in a new era of efficiency and innovation. Machine learning algorithms analyze vast datasets, predicting peptide structures with high binding affinities and enhancing the success rate of drug candidates. Additionally, AI helps in the identification of potential adverse events and optimization of pharmacokinetic properties, contributing to the overall quality of peptide therapeutics. Pharmaceutical companies such as ProteinQure have developed an extensive portfolio of peptide therapeutics using computational tools, while others like Space Peptides provide contract services to grant access to their machine learning and AI tools to design and produce premium peptide drugs.

The escalating interest of large pharmaceutical companies in peptide drugs is evident from the rapidly expanding global pipeline of peptide therapeutics. In addition, a surge of collaborations and strategic partnerships has been observed in the recent months within the pharmaceutical industry, some of these involving prominent pharmaceutical companies including Eli Lilly and AstraZeneca. Recognizing the potential of peptides to address unmet medical needs, prominent companies are aggressively seeking to expand their peptide portfolios through joint ventures, licensing agreements and acquisitions, which allow resource pooling and utilization of combined knowledge, thereby accelerating the development and commercialization of peptide drugs.

Peptide drugs are expected to play a significant role in the future landscape of the global pharmaceutical market. The growing understanding of disease causes at molecular levels coincides with the precision targeting abilities of peptides, making them a cornerstone in personalized medicine. Continuous advances in peptide engineering, together with the incorporation of AI, will almost certainly result in the development of highly effective and well-tolerated treatments. As the pharmaceutical industry move toward patient-centric paradigm, the adaptability and specificity of peptide drugs positions them as frontrunners in addressing the shifting healthcare landscape. Peptides' adaptability across therapeutic areas, paired with their good safety rating, makes them an appealing choice for pharmaceutical companies seeking to fulfil patients' medical diverse needs.

In conclusion, the journey through the realm of peptide drugs reveals an extensive array of innovation and potential. As we approach a new era in pharmaceuticals, peptides appear as more than merely therapeutic and diagnostic agents, but also as forerunners of a paradigm shift in healthcare. Peptides will play a crucial role in personalized medicine, targeted therapeutics, and the ever-expanding panorama of precision healthcare in the future. The combination of cutting-edge technology like AI with the inherent versatility of peptides opens the door to exceptional developments. The expanding peptide drugs narrative pains a captivating vision of a future in which these molecules continue to push the bounds of medical possibility, delivering innovative treatments and optimisms on the horizon.

Table of Contents

1. Introduction to Peptide Drugs

• 1.1. History, Development & Evolution
• 1.2. Approved Peptide Drugs

2. Peptide Drugs - Therapeutic, Diagnostic & Theranostic Potential & Market Implications

• 2.1. Therapeutic Potential & Market Implications
• 2.2. Diagnostic Potential & Market Implications
• 2.3. Theranostic Potential & Market Implications

3. Global Peptide Drugs Clinical Research & Market Trends by Indication

• 3.1. Inheritable Genetic Diseases
• 3.2. Cancer
• 3.3. Microbial Infections
• 3.4. Autoimmune Disorders
• 3.5. Metabolic Disorders
• 3.6. Neurodegenerative Diseases

4. Peptide Based Therapeutic Approaches

• 4.1. Peptide Hormone Drugs
• 4.2. Peptide Drug Conjugates
• 4.3. Peptide Vaccines
• 4.4. Peptide Agonists
• 4.5. Peptide Aptamers
• 4.6. Peptide Antibody

5. Global Peptide Therapeutics Market Outlook

• 5.1. Current Market Trends & Drivers
• 5.2. Future Growth Avenues

6. Peptide Therapeutics Market Landscape by Region

• 6.1. US
• 6.2. EU
• 6.3. China
• 6.4. Japan
• 6.5. South Korea
• 6.6. UK
• 6.7. India
• 6.8. Middle East
• 6.9. Canada
• 6.10. Australia

7. Global Peptide Therapeutics Clinical Trials Overview

• 7.1. By Country
• 7.2. Indication
• 7.3. Phase
• 7.4. Priority Status
• 7.5. Therapy Class

8. Marketed Peptide Drugs Insight - Patent, Availability, Cost, Dosage, & Sales Insight

• 8.1. Bylvay
  • 8.1.1. Overview
  • 8.1.2. Pricing & Dosage Analysis
  • 8.1.3. Sales Insight
• 8.2. Parsabiv
  • 8.2.1. Overview & PatentS Insight
  • 8.2.2. Pricing & Dosage Analysis
  • 8.2.3. Sales Insight
• 8.3. Bydureon BCise
  • 8.3.1. Overview & Patent Insight
  • 8.3.2. Pricing & Dosage Analysis
  • 8.3.3. Sales Insight
• 8.4. Linzess
  • 8.4.1. Overview & Patent Insight
  • 8.4.2. Pricing & Dosage Insight
  • 8.4.3. Sales Insight
• 8.5. Increlex
  • 8.5.1. Overview & Patent Insight
  • 8.5.2. Pricing & Dosage Insight
  • 8.5.3. Sales Analysis
• 8.6. Terlivaz
  • 8.6.1. Overview & Patent Insight
  • 8.6.2. Pricing & Dosage Insight
  • 8.6.3. Sales Analysis
• 8.7. Empaveli
  • 8.7.1. Overview & Patent Insight
  • 8.7.2. Pricing & Dosage Insight
  • 8.7.3. Sales Analysis
• 8.8. Voxzogo
  • 8.8.1. Overview & Patent Insight
  • 8.8.2. Pricing & Dosage Insight
  • 8.8.3. Sales Analysis
• 8.9. Imcivree
  • 8.9.1. Overview & Patent Insight
  • 8.9.2. Pricing & Dosage Insight
  • 8.9.3. Sales Analysis
• 8.10. Trulicity
  • 8.10.1. Overview & Patent Insight
  • 8.10.2. Pricing & Dosage Insight
  • 8.10.3. Sales Analysis
• 8.11. Ozempic
  • 8.11.1. Overview & Patent Insight
  • 8.11.2. Pricing & Dosage Insight
  • 8.11.3. Sales Analysis
• 8.12. Wegovy
  • 8.12.1. Overview & Patent Insight
  • 8.12.2. Pricing & Dosage Insight
  • 8.12.3. Sales Analysis
• 8.13. Tresiba
  • 8.13.1. Overview & Patent Insight
  • 8.13.2. Pricing & Dosage Insight
  • 8.13.3. Sales Analysis
• 8.14. Rybelsus
  • 8.14.1. Overview & Patent Insight
  • 8.14.2. Pricing & Dosage Insight
  • 8.14.3. Sales Analysis
• 8.15. Xultophy
  • 8.15.1. Overview & Patent Insight
  • 8.15.2. Pricing & Dosage Insight
  • 8.15.3. Sales Analysis
• 8.16. Victoza
  • 8.16.1. Overview & Patent Insight
  • 8.16.2. Pricing & Dosage Insight
  • 8.16.3. Sales Analysis
• 8.17. Ryzodeg
  • 8.17.1. Overview & Patent Insight
  • 8.17.2. Pricing & Dosage Insight
  • 8.17.3. Sales Analysis
• 8.18. Fiasp
  • 8.18.1. Overview & Patent Insight
  • 8.18.2. Pricing & Dosage Insight
  • 8.18.3. Sales Analysis
• 8.19. Lantus
  • 8.19.1. Overview & Patent Insight
  • 8.19.2. Pricing & Dosage Insight
  • 8.19.3. Sales Analysis
• 8.20. Toujeo
  • 8.20.1. Overview & Patent Insight
  • 8.20.2. Pricing & Dosage Insight
  • 8.20.3. Sales Analysis

9. Peptide Therapeutics Development Technologies Platform

• 9.1. Biodrug Design Accelerator - Fujitsu/PeptiDream
• 9.2. T-Win® Technology - IO Biotech
• 9.3. Numatech - Numaferm
• 9.4. ProteinStudio - ProteinQure
• 9.5. The Magnifier NφΦ™ - Nuritas
• 9.6. PepPower - GenScript
• 9.7. Unnamed Peptide Platform - Zealand Pharma
• 9.8. PDPS (Peptide Discovery Platform System) - PeptiDream
• 9.9. Veneno Suite - Veneno Technologies
• 9.10. SmartDepot™ Technology - Peptron
• 9.11. Bicycles - Bicycle Therapeutics
• 9.12. RALA Technolgy - pHion Therapeutics
• 9.13. Discovery Platform - Orbit Discovery
• 9.14. Imotopes - Imcyse
• 9.15. Nautilus - Peptilogics
• 9.16. Swarm Intelligence 2.0 - Pepticom
• 9.17. streaMLine Platform - Gubra
• 9.18. Precision Endocrine Peptides (PEPs) - MBX Biosciences
• 9.19. pHLIP (pH-Low Insertion Peptides) - pHLIP
• 9.20. alphalex - Cybrexa

10. Cyclic Peptides Clinical Trials Insight By Country, Indication & Phase

• 10.1. Research
• 10.2. Preclinical
• 10.3. Phase-I
• 10.4. Phase-I/II
• 10.5. Phase-II
• 10.6. Phase-II/III
• 10.7. Phase-III
• 10.8. Preregistration
• 10.9. Registered
• 10.10. Marketed

11. Peptide Hormones Clinical Trials Insight By Country, Indication & Phase

• 11.1. Research
• 11.2. Preclinical
• 11.3. Phase-I
• 11.5. Phase-I/II
• 11.6. Phase-II
• 11.7. Phase-II/III
• 11.8. Phase-III
• 11.9. Preregistration
• 11.10. Registered
• 11.11. Marketed

12. Peptides Clinical Trials Insight By Country, Indication & Phase

• 12.1. Research
• 12.2. Preclinical
• 12.3. Phase-I
• 12.4. Phase-I/II
• 12.5. Phase-II
• 12.6. Phase-II/III
• 12.7. Phase-III
• 12.8. Preregistration
• 12.9. Registered
• 12.10. Marketed

13. Glucagon-Like Peptides Clinical Trials Insight By Country, Indication & Phase

• 13.1. Preclinical
• 13.2. Phase-I
• 13.3. Phase-I/II
• 13.4. Phase-II
• 13.5. Phase-III
• 13.6. Marketed

14. Oligopeptides Clinical Trials Insight By Country, Indication & Phase

• 14.1. Research
• 14.2. Preclinical
• 14.3. Phase-I
• 14.4. Phase-I/II
• 14.5. Phase-II
• 14.6. Phase-II/III
• 14.7. Phase-III
• 14.8. Registered
• 14.9. Marketed

15. Lipopeptides Clinical Trials Insight By Country, Indication & Phase

• 15.1. Research
• 15.2. Preclinical
• 15.3. Phase-II
• 15.4. Marketed

16. Dipeptides Clinical Trials Insight By Country, Indication & Phase

• 16.1. Research
• 16.2. Preclinical
• 16.3. Phase-I
• 16.4. Phase-II
• 16.5. Phase-III
• 16.6. Registered
• 16.7. Marketed

17. Depsipeptides Clinical Trials Insight By Country, Indication & Phase

• 17.1. Preclinical
• 17.2. Phase-I
• 17.3. Phase-II
• 17.4. Marketed

18. Glycopeptides Clinical Trials Insight By Country, Indication & Phase

• 18.1. Preclinical
• 18.2. Phase-I
• 18.3. Phase-I/II
• 18.5. Phase-II
• 18.6. Phase-III
• 18.8. Marketed

19. Peptide Vaccines Clinical Trials Insight By Country, Indication & Phase

• 19.1. Preclinical
• 19.2. Phase-I/II
• 19.3. Phase-II
• 19.4. Phase-III
• 19.5. Registered
• 19.6. Marketed

20. Peptide Fragments Clinical Trials Insight By Country, Indication & Phase

• 20.1. Preclinical
• 20.2. Phase-I
• 20.3. Phase-II
• 20.4. Phase-III
• 20.5. Preregistration
• 20.6. Registered
• 20.7. Marketed

21. Opioid Peptides Clinical Trials Insight By Country, Indication & Phase

• 21.1. Research
• 21.2. Preclinical
• 21.3. Phase-I
• 21.4. Phase-II
• 21.5. Preregistration
• 21.6. Registered
• 21.7. Marketed

22. Natriuretic Peptides Clinical Trials Insight By Country, Indication & Phase

• 22.1. Preclinical
• 22.2. Phase-I
• 22.3. Phase-II
• 22.4. Phase-II/III
• 22.5. Phase-III
• 22.6. Marketed

23. Neuropeptides Clinical Trials Insight By Country, Indication & Phase

• 23.1. Research
• 23.2. Preclinical
• 23.3. Phase-I
• 23.4. Phase-I/II
• 23.5. Phase-II
• 23.6. Marketed

24. Antimicrobial Cationic Peptides Clinical Trials Insight By Country, Indication & Phase

• 24.1. Preclinical
• 24.2. Phase-I
• 24.3. Phase-III

25. Peptide Hydrolases Clinical Trials Insight By Country, Indication & Phase

• 25.1. Phase-II

26. Peptide Aptamers

• 26.1. Research
• 26.2. Preclinical
• 26.3. Phase-I
• 26.4. Phase-II

27. Intercellular Signalling Peptides Clinical Trials Insight By Country, Indication & Phase

• 27.1. Phase-II

28. Peptide Antibiotics Clinical Trials Insight By Country, Indication & Phase

• 28.1. Phase-I

29. Peptide Drug Conjugates Clinical Trials Insight By Country, Indication & Phase

• 29.1. Preclinical

30. Bicyclic Peptides Clinical Trials Insight By Country, Indication & Phase

• 30.1. Preclinical

31. Multiple Peptides Clinical Trials Insight By Country, Indication & Phase

• 31.1. Research
• 31.2. Preclinical
• 31.3. Phase-I
• 31.4. Phase-I/II
• 31.5. Phase-II
• 31.6. Preregistration
• 31.7. Registered
• 31.8. Marketed

32. Competitive Landscape

• 32.1. AbbVie
• 32.2. Adocia
• 32.3. Amgen
• 32.4. Antlia Bioscience
• 32.5. AsclepiX Therapeutics
• 32.6. AstraZeneca
• 32.7. Bicycle Therapeutics
• 32.8. Biohaven Labs
• 32.9. Bristol-Myers Squibb
• 32.10. Carmot Therapeutics
• 32.11. Eli Lilly and Company
• 32.12. Ferring Pharmaceuticals
• 32.13. Gan&Lee Pharmaceuticals
• 32.14. GEROPHARM
• 32.15. Hanmi Pharmaceutical
• 32.16. HEC Pharm
• 32.17. Heidelberg Pharma AG
• 32.18. ImCyse
• 32.19. Janux Therapeutics
• 32.20. Kine Sciences
• 32.21. Lactocore
• 32.22. Maxwell Biosciences
• 32.23. Merck & Co
• 32.24. Novartis
• 32.25. Novo Nordisk
• 32.26. Oryn Therapeutics
• 32.27. Palatin Technologies
• 32.28. PeptiDream
• 32.29. Pfizer
• 32.30. Priavoid
• 32.31. Primary Peptides
• 32.32. Protagonist Therapeutics
• 32.33. Roche
• 32.34. Sanofi
• 32.35. Sapience Therapeutics
• 32.36. Seagen
• 32.37. Shaanxi Micot Technology Co
• 32.38. Stuart Therapeutics
• 32.39. Takeda
• 32.40. Zealand Pharma

List of Figures

• Figure 1-1: Landmarks in Peptides Drugs Market
• Figure 3-1: Pro00013585 Phase II Study - Initiation & Completion Years
• Figure 3-2: STUDY0000567 Phase II Study - Initiation & Completion Years
• Figure 3-3: NCT05378672 Phase III Study - Initiation & Completion Years
• Figure 3-4: ZP4207-21052 Phase III Study - Initiation & Completion Years
• Figure 3-5: GLSI-21-01 Phase III Study - Initiation & Completion Years
• Figure 3-6: IO102-IO103-013 Phase III Study - Initiation & Completion Years
• Figure 3-7: NCT06091748 Phase II Study - Initiation & Completion Years
• Figure 3-8: PMC67199 Phase I Study - Initiation & Completion Years
• Figure 3-9: ACW-1221958-1 Phase II Study - Initiation & Completion Years
• Figure 3-10: NCT05841095 Phase I/II Study - Initiation & Completion Years
• Figure 3-11: NCT05340790 Phase I Study - Initiation & Completion Years
• Figure 3-12: IR902-007 Phase I Study - Initiation & Completion Years
• Figure 3-13: ISEMIS Phase I/II Study - Initiation & Completion Years
• Figure 3-14: YN011-301 Phase II/III Study - Initiation & Completion Years
• Figure 3-15: SCW0502-1031 Phase III Study - Initiation & Completion Years
• Figure 3-16: NCT05202353 Phase I Study - Initiation & Completion Years
• Figure 3-17: NCT04305002 Phase II Study - Initiation & Completion Years
• Figure 3-18: NCT05189210 Phase II Study - Initiation & Completion Years
• Figure 3-19: ALZ-C-001 Phase II Study - Initiation & Completion Years
• Figure 3-20: ELViS-FA Phase I/II Study - Initiation & Completion Years
• Figure 3-21: NCT05634876 Phase II Study - Initiation & Completion Years
• Figure 4-1: CUV104 Phase II Study - Initiation & Completion Years
• Figure 4-2: CUV152 Phase II Study - Initiation & Completion Years
• Figure 4-3: Peptide-Drug Conjugate Structure
• Figure 4-4: NCT04706962 Phase I Study - Initiation & Completion Years
• Figure 4-5: MLB-PK-001 Early Phase I Study - Initiation & Completion Year
• Figure 4-6: ANGLeD Phase III Study - Initiation & Completion Years
• Figure 4-7: CA209-8TX Phase I/II Study - Initiation & Completion Years
• Figure 4-8: CLAUDE/EOCRC1-22 Phase II Study - Initiation & Completion Years
• Figure 4-9: COVENANT Phase III Study - Initiation & Completion Years
• Figure 4-10: EGRABIS1 Phase II Study - Initiation & Completion Years
• Figure 4-11: GLIMP Phase II Study - Initiation & Completion Years
• Figure 4-12: NCT05530577 Phase II Study - Initiation & Completion Years
• Figure 5-1: Global - Peptide Therapeutic Market Size (US$ Billion), 2022 - 2029
• Figure 5-2: Global - Peptide Oncology Drugs Market Size (US$ Billion), 2022 - 2029
• Figure 5-3: Ongoing Trends in Peptide Drugs Market
• Figure 5-4: Future Growth Avenues in Peptide Drugs Market
• Figure 6-1: China - Estimated Diabetes Population (Million), 2021 & 2030
• Figure 6-2: India - Estimated Diabetes Population (Million), 2021 & 2030
• Figure 6-3: ME - Estimated Diabetes Population in Saudi Arabia & UAE (Million), 2021 & 2030
• Figure 6-4: Canada - Estimated Diabetes Population (Million), 2021 & 2030
• Figure 7-1: Global - Peptides Clinical Trials by Country (Numbers), 2023 Till 2029
• Figure 7-2: Global - Peptides Clinical Trials by Indication (Numbers), 2023 Till 2029
• Figure 7-3: Global - Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-4: Global - Cyclic Peptide Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-5: Global - Peptide Hormones Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-6: Global - Glucagon-Like Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-7: Global - Oligopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-8: Global - Lipopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-9: Global - Dipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-10: Global - Depsipeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-11: Global - Glycopeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-12: Global - Peptide Vaccines Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-13: Global - Peptide Fragments Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-14: Global - Opioid Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-15: Global - Natriuretic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-16: Global - Neuropeptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-17: Global - Antimicrobial Cationic Peptides Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-18: Global - Peptide Aptamers Clinical Trials by Phase (Numbers), 2023 till 2029
• Figure 7-19: Global - Peptides Clinical Trials by Priority Status (Numbers), 2023 Till 2029
• Figure 7-20: Global - Peptides Clinical Trials by Therapy Class (Numbers), 2023 Till 2029
• Figure 8-1: US - Cost per Unit & Supply of Bylvay Oral Capsules (US$), November'2023
• Figure 8-2: US - Cost per Unit & Supply of Bylvay Oral Pellets (US$), November'2023
• Figure 8-3: EU - Cost per Unit & Supply of Bylvay Oral Capsules & Pellets (Eur/US$), November'2023
• Figure 8-4: Global - Quarterly Bylvay Sales (US$ Million), 2023
• Figure 8-5: NA - Quarterly Bylvay Sales (US$ Million), 2023
• Figure 8-6: Europe - Quarterly Bylvay Sales (US$ Million), 2023
• Figure 8-7: ROW - Quarterly Bylvay Sales (US$ Million), 2023
• Figure 8-8: Parsabiv - US Patents Expiration Years
• Figure 8-9: Parsabiv - Europe Patents Expiration Years
• Figure 8-10: Parsabiv - Cost per Unit & Supply (US$), November'2023
• Figure 8-11: Global - Annual Parsabiv Sales (US$ Million), 2019-2023
• Figure 8-12: US - Annual Parsabiv Sales (US$ Million), 2019-2023
• Figure 8-13: ROW - Annual Parsabiv Sales (US$ Million), 2019-2023
• Figure 8-14: Global - Quarterly Parsabiv Sales (US$ Million), 2023
• Figure 8-15: US - Quarterly Parsabiv Sales (US$ Million), 2023
• Figure 8-16: ROW - Quarterly Parsabiv Sales (US$ Million), 2023
• Figure 8-17: Global - Quarterly Parsabiv Sales (US$ Million), 2022
• Figure 8-18: US - Quarterly Parsabiv Sales (US$ Million), 2022
• Figure 8-19: ROW - Quarterly Parsabiv Sales (US$ Million), 2022
• Figure 8-20: Bydureon - Year of Approval and Expiry of Patents for Injection
• Figure 8-21: Bydureon - Year of Approval and Expiry of Patents for Injection
• Figure 8-22: Bydureon BCise - Cost per Unit & Supply (US$), November'2023
• Figure 8-23: Global - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-24: US - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-25: Europe - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-26: EM - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-27: ROW - Annual Bydureon Sales (US$ Million), 2019-2023
• Figure 8-28: Global - Quarterly Bydureon Sales (US$ Million), 2023
• Figure 8-29: US - Quarterly Bydureon Sales (US$ Million), 2023
• Figure 8-30: Europe - Quarterly Bydureon Sales (US$ Million), 2023
• Figure 8-31: EM - Quarterly Bydureon Sales (US$ Million), 2023
• Figure 8-32: Global - Quarterly Bydureon Sales (US$ Million), 2022
• Figure 8-33: US - Quarterly Bydureon Sales (US$ Million), 2022
• Figure 8-34: Europe - Quarterly Bydureon Sales (US$ Million), 2022
• Figure 8-35: EM - Quarterly Bydureon Sales (US$ Million), 2022
• Figure 8-36: Linzess - Cost per Unit & Supply (US$), November'2023
• Figure 8-37: Linzess - Dosage by Indication (mcg)
• Figure 8-38: Global - Annual Linzess Sales (US$ Million), 2020-2023
• Figure 8-39: US - Annual Linzess Sales (US$ Million), 2020-2023
• Figure 8-40: ROW - Annual Linzess Sales (US$ Million), 2019-2023
• Figure 8-41: Global - Quarterly Linzess Sales (US$ Million), 2023
• Figure 8-42: US - Quarterly Linzess Sales (US$ Million), 2023
• Figure 8-43: ROW - Quarterly Linzess Sales (US$ Million), 2023
• Figure 8-44: Global - Quarterly Linzess Sales (US$ Million), 2022
• Figure 8-45: US - Quarterly Linzess Sales (US$ Million), 2022
• Figure 8-46: ROW - Quarterly Linzess Sales (US$ Million), 2022
• Figure 8-47: Increlex - US & EU Patent Expiry Years
• Figure 8-48: Increlex - Cost per Unit & Supply (US$), November'2023
• Figure 8-49: Global - Annual Increlex Sales (US$ Million), 2019-2023
• Figure 8-50: Global - Quarterly Increlex Sales (US$ Million), 2023
• Figure 8-51: Global - Quarterly Increlex Sales (US$ Million), 2022
• Figure 8-52 : Terlivaz - Dosing Chart
• Figure 8-53: Global - Quarterly Terlivaz Sales (US$ Million), 2023
• Figure 8-54: Empaveli - Cost per Unit & Supply (US$), November'2023
• Figure 8-55: Empaveli - Cost of Monthly & Yearly Treatment (US$), November'2023
• Figure 8-56: Global - Annual Empaveli Sales (US$ Million), 2021-2023
• Figure 8-57: US - Annual Empaveli Sales (US$ Million), 2021-2023
• Figure 8-58: ROW - Annual Empaveli Sales (US$ Million), 2021-2023
• Figure 8-59: Global - Quarterly Increlex Sales (US$ Million), 2023
• Figure 8-60: US - Quarterly Empaveli Sales (US$ Million), 2023
• Figure 8-61: ROW - Quarterly Empaveli Sales (US$ Million), 2023
• Figure 8-62: Global - Quarterly Increlex Sales (US$ Million), 2022
• Figure 8-63: US - Annual Empaveli Sales (US$ Million), 2022
• Figure 8-64: ROW - Annual Empaveli Sales (US$ Million), 2022
• Figure 8-65: Voxzogo - Cost per Unit & Supply (US$), November'2023
• Figure 8-66: Global - Annual Voxzogo Sales (US$ Million), 2021-2023
• Figure 8-67: Global - Quarterly Voxzogo Sales (US$ Million), 2023
• Figure 8-68: Global - Quarterly Voxzogo Sales (US$ Million), 2022
• Figure 8-69: Global - Annual Imcivree Sales (US$ Million), 2021-2023
• Figure 8-70: Global - Quarterly Imcivree Sales (US$ Million), 2023
• Figure 8-71: Global - Quarterly Imcivree Sales (US$ Million), 2022
• Figure 8-72: Voxzogo - Cost per Unit & Supply (US$), November'2023
• Figure 8-73: Global - Annual Trulicity Sales (US$ Million), 2019-2023
• Figure 8-74: Global - Quarterly Trulicity Sales (US$ Million), 2023
• Figure 8-75: Global - Quarterly Trulicity Sales (US$ Million), 2022
• Figure 8-76: Ozempic - Cost per Unit & Supply (US$), November'2023
• Figure 8-77: Ozempic - Initiation and Increment Doses (mg/week)
• Figure 8-78: Global - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-79: NA - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-80: EMEA - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-81: China - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-82: ROW - Annual Ozempic Sales (US$ Million), 2019-2023
• Figure 8-83: Global - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-84: NA - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-85: EMEA - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-86: China - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-87: ROW - Quarterly Ozempic Sales (US$ Million), 2023
• Figure 8-88: Global - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-89: NA - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-90: EMEA - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-91: China - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-92: ROW - Quarterly Ozempic Sales (US$ Million), 2022
• Figure 8-93: Wegovy - Cost per Unit & Supply of 0.25mg, 0.5mg and 1mg Solutions (US$), November'2023
• Figure 8-94: Wegovy - Cost per Unit & Supply of 1.7mg, and 2.4mg Solutions (US$), November'2023
• Figure 8-95: Global - Annual Wegovy Sales (US$ Million), 2021-2023
• Figure 8-96: NA - Annual Wegovy Sales (US$ Million), 2021-2023
• Figure 8-97: EMEA - Annual Wegovy Sales (US$ Million), 2021-2023
• Figure 8-98: Global - Quarterly Wegovy Sales (US$ Million), 2023
• Figure 8-99: NA - Quarterly Wegovy Sales (US$ Million), 2023
• Figure 8-100: EMEA - Quarterly Wegovy Sales (US$ Million), 2023
• Figure 8-101: Global - Quarterly Wegovy Sales (US$ Million), 2022
• Figure 8-102: NA - Quarterly Wegovy Sales (US$ Million), 2022
• Figure 8-103: EMEA - Quarterly Wegovy Sales (US$ Million), 2022
• Figure 8-104: Tresiba - Cost per Unit & Supply of 100 units/mL Solution (US$), November'2023
• Figure 8-105: Tresiba - Cost per Unit & Supply of 200 units/mL Solution (US$), November'2023
• Figure 8-106: Insulin degludec - Cost per Unit & Supply of 100 units/mL Solution (US$), November'2023
• Figure 8-107: Global - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-108: NA - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-109: EMEA - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-110: China - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-111: ROW - Annual Tresiba Sales (US$ Million), 2019-2023
• Figure 8-112: Global - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-113: NA - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-114: EMEA - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-115: China - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-116: ROW - Quarterly Tresiba Sales (US$ Million), 2023
• Figure 8-117: Global - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-118: NA - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-119: EMEA - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-120: China - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-121: ROW - Quarterly Tresiba Sales (US$ Million), 2022
• Figure 8-122: Rybelsus - Cost per Unit & Supply (US$), November'2023
• Figure 8-123: Global - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-124: NA - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-125: EMEA - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-126: China - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-127: ROW - Annual Rybelsus Sales (US$ Million), 2019-2023
• Figure 8-128: Global - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-129: NA - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-130: EMEA - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-131: China - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-132: ROW - Quarterly Rybelsus Sales (US$ Million), 2023
• Figure 8-133: Global - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-134: NA - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-135: EMEA - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-136: China - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-137: ROW - Quarterly Rybelsus Sales (US$ Million), 2022
• Figure 8-138: Xultophy - Cost per Unit & Supply (US$), November'2023
• Figure 8-139: Global - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-140: NA - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-141: EMEA - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-142: China - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-143: ROW - Annual Xultophy Sales (US$ Million), 2019-2023
• Figure 8-144: Global - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-145: NA - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-146: EMEA - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-147: China - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-148: ROW - Quarterly Xultophy Sales (US$ Million), 2023
• Figure 8-149: Global - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-150: NA - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-151: EMEA - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-152: China - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-153: ROW - Quarterly Xultophy Sales (US$ Million), 2022
• Figure 8-154: Victoza - Cost per Unit & Supply (US$), November'2023
• Figure 8-155: Global - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-156: North America - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-157: EMEA - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-158: China - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-159: ROW - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-160: Global - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-161: North America - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-162: EMEA - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-163: China - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-164: ROW - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-165: Global - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-166: North America - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-167: EMEA - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-168: China - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-169: ROW - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-170: Global - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-171: EMEA - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-172: China - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-173: ROW - Annual Victoza Sales (US$ Million), 2019-2023
• Figure 8-174: Global - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-175: EMEA - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-176: China - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-177: ROW - Quarterly Victoza Sales (US$ Million), 2023
• Figure 8-178: Global - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-179: EMEA - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-180: China - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-181: ROW - Quarterly Victoza Sales (US$ Million), 2022
• Figure 8-182: Fiasp - Cost per Unit & Supply (US$), November'2023
• Figure 8-183: Global - Annual Fiasp Sales (US$ Million), 2019-2023
• Figure 8-184: NA - Annual Fiasp Sales (US$ Million), 2019-2023
• Figure 8-185: EMEA - Annual Fiasp Sales (US$ Million), 2019-2023
• Figure 8-186: ROW - Annual Fiasp Sales (US$ Million), 2019-2023
• Figure 8-187: Global - Quarterly Fiasp Sales (US$ Million), 2023
• Figure 8-188: NA - Quarterly Fiasp Sales (US$ Million), 2023
• Figure 8-189: EMEA - Quarterly Fiasp Sales (US$ Million), 2023
• Figure 8-190: ROW - Quarterly Fiasp Sales (US$ Million), 2023
• Figure 8-191: Global - Quarterly Fiasp Sales (US$ Million), 2022
• Figure 8-192: NA - Quarterly Fiasp Sales (US$ Million), 2022
• Figure 8-193: EMEA - Quarterly Fiasp Sales (US$ Million), 2022
• Figure 8-194: ROW - Quarterly Fiasp Sales (US$ Million), 2022
• Figure 8-195: Lantus - Cost per Unit & Supply (US$), November'2023
• Figure 8-196: Insulin Glargine & Insulin Glargine-yfgn - Cost per Unit & Supply (US$), November'2023
• Figure 8-197: Global - Annual Lantus Sales (US$ Million), 2019-2023
• Figure 8-198: US - Annual Lantus Sales (US$ Million), 2019-2023
• Figure 8-199: Europe - Annual Lantus Sales (US$ Million), 2019-2023
• Figure 8-200: ROW - Annual Lantus Sales (US$ Million), 2019-2023
• Figure 8-201: Global - Quarterly Lantus Sales (US$ Million), 2023
• Figure 8-202: US - Quarterly Lantus Sales (US$ Million), 2023
• Figure 8-203: Europe - Quarterly Lantus Sales (US$ Million), 2023
• Figure 8-204: ROW - Quarterly Lantus Sales (US$ Million), 2023
• Figure 8-205: Global - Quarterly Lantus Sales (US$ Million), 2022
• Figure 8-206: US - Quarterly Lantus Sales (US$ Million), 2022
• Figure 8-207: Europe - Quarterly Lantus Sales (US$ Million), 2022
• Figure 8-208: ROW - Quarterly Lantus Sales (US$ Million), 2022
• Figure 8-209: Toujeo - US Patent Acceptance & Expiration Years
• Figure 8-210: Toujeo - Cost per Unit & Supply (US$), November'2023
• Figure 8-211: Global - Annual Toujeo Sales (US$ Million), 2019-2023
• Figure 8-212: US - Annual Toujeo Sales (US$ Million), 2019-2023
• Figure 8-213: Europe - Annual Toujeo Sales (US$ Million), 2019-2023
• Figure 8-214: ROW - Annual Toujeo Sales (US$ Million), 2019-2023
• Figure 8-215: Global - Quarterly Toujeo Sales (US$ Million), 2023
• Figure 8-216: US - Quarterly Toujeo Sales (US$ Million), 2023
• Figure 8-217: Europe - Quarterly Toujeo Sales (US$ Million), 2023
• Figure 8-218: ROW - Quarterly Toujeo Sales (US$ Million), 2023
• Figure 8-219: Global - Quarterly Toujeo Sales (US$ Million), 2022
• Figure 8-220: US - Quarterly Toujeo Sales (US$ Million), 2022
• Figure 8-221: Europe - Quarterly Toujeo Sales (US$ Million), 2022
• Figure 8-222: ROW - Quarterly Toujeo Sales (US$ Million), 2022
• Figure 9-1: Biodrug Design Accelerator - Technical Benefits
• Figure 9-2: Biodrug Design Accelerator - Technical Benefits
• Figure 9-3: IO Biotech - T-win Technology
• Figure 9-4: Numatech - Numaferm Platform
• Figure 9-5: Nuritas - Scientific Achievements of Magnifier NφΦ Bioactive Peptide Discovery Platform
• Figure 9-6: Nuritas - The Magnifier NφΦ Bioactive Peptide Discovery Process
• Figure 9-7: Nuritas - The Magnifier NφΦ Bioactive Peptide Results
• Figure 9-8: GenScript - PepPower Technology
• Figure 9-9: PeptiDream - PDPS Outline
• Figure 9-10: PeptiDream - PDPS Outline
• Figure 9-11: PeptiDream - PDPS Features
• Figure 9-12: Benefits of DRPs as Drug Molecule Scaffold
• Figure 9-13: Veneno Technologies - Veneno Suite Components
• Figure 9-14: Veneno Technologies - Veneno Suite Process
• Figure 9-15: Peptron - SmartDepot™ Features
• Figure 9-16: Peptron - SmartDepot™ Manufacturing Scheme
• Figure 9-17: Bicycle Therapeutics - Bicycles Key Properties
• Figure 9-18: Bicycle Therapeutics - Bicycles Key Properties
• Figure 9-19: pHion Therapeutics - RALA Nanoparticles Advantages
• Figure 9-20: pHion Therapeutics - RALA Nanoparticles BENEFITS
• Figure 9-21: Orbit Discovery - Orbit Peptide Display Engine
• Figure 9-22: Benefits of Imotopes over Current Therapies
• Figure 9-23: Peptilogics - Peptide Development Process
• Figure 9-24: Peptilogics - Nautilus Features
• Figure 9-25: Pepticom - Swarm Intelligence 2.0 AI platform
• Figure 9-26: Cybrexa - alphalex Selective Tumor Cell Targeting

List of Tables

• Table 1-1: Landmarks in Peptides Drugs Market
• Table 6-1: US - Recent FDA Designations for Peptide Drug Candidates
• Table 8-1: Bylvay - Recommended Dosage for 40 mcg/kg/day
• Table 8-2: Parsabiv - Recommended Schedule for Monitoring Corrected Serum Calcium and Parathyroid Hormone Levels during Treatment
• Table 8-3: Voxzogo - Recommended Daily Dosage and Injection Volume
• Table 8-4: Wegovy - Recommended Dosage Regimen for Adults
• Table 8-5: Wegovy - Recommended Dosage Regimen for Pediatric Patients Aged 12 Years and Older
• Table 9-1: GenScript - PepPower™ Platform Advantages